Naftifine

INTRODUCTION

Indications

Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Action

Affects the synthesis of the fungal cell wall. Therapeutic Effects: Decrease in symptoms of fungal infection.

Adverse Reactions/Side Effects

Local: burning, dryness, itching, local hypersensitivity reactions, redness, stinging.

PHYSICAL THERAPY IMPLICATIONS

Examination and Evaluation

• Assess healing of skin lesions to help document drug effectiveness.

Interventions

• Avoid contact with cutaneous lesions when treating patient.

• Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection.

Patient/Client-Related Instruction

• Advise patient to report any increased local sensitivity to this drug (pain, burning, itching, swelling).

• Instruct patient about proper hygiene; e.g., thoroughly wash and dry the affected area, wear clean socks and ventilated shoes for tinea pedis, and so forth.

• Advise patient to apply the drug as directed for the full course of treatment even if feeling better.

• Inform patient that early relief of cutaneous symptoms may be seen in 2–3 days. Full therapeutic response may take up to 4 wk.

• Advise patient to seek medical help if infections persist or recur after the full treatment.

  Recurrent fungal infections may be a sign of systemic illness.

Pharmacokinetics

Absorption: Absorption through intact skin is minimal.

Distribution: Distribution after topical administration is primarily local.

Metabolism and Excretion: Systemic metabolism and excretion not known following local application.

Half-life: Not applicable.

Contraindications/Precautions

Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Contains alcohol and should be avoided in patients with known intolerance.

Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); OB/Lactation: Safety not established.

Interactions

Drug-Drug: Not known.

Route/Dosage

Topical (Adults): Apply cream once daily for up to 4 wk. Apply gel bid for up to 4 wk.

Availability

Cream: 1%. Gel: 1%.